Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016

Watchlist Manager
Shanghai MicroPort Endovascular MedTech Group Co Ltd Logo
Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
Watchlist
Price: 105.26 CNY -3.02% Market Closed
Market Cap: 13B CNY
Have any thoughts about
Shanghai MicroPort Endovascular MedTech Group Co Ltd?
Write Note

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
Net Income (Common)
ÂĄ492.4m
CAGR 3-Years
32%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Net Income (Common)
ÂĄ1.9B
CAGR 3-Years
-6%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
Net Income (Common)
ÂĄ304m
CAGR 3-Years
47%
CAGR 5-Years
72%
CAGR 10-Years
N/A
Autobio Diagnostics Co Ltd
SSE:603658
Net Income (Common)
ÂĄ1.3B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
Net Income (Common)
ÂĄ580.4m
CAGR 3-Years
-47%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Net Income (Common)
ÂĄ1.7B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Glance View

Market Cap
13B CNY
Industry
Health Care

Shanghai MicroPort Endovascular MedTech Group Co Ltd stands as a testament to China's burgeoning capabilities in the medtech landscape. The company was born from a vision to develop innovative solutions for treating cardiovascular diseases, which are among the leading causes of mortality worldwide. MicroPort Endovascular crafts specialized medical devices aimed at minimally invasive therapies, particularly in the vascular intervention domain. They produce stents, embolization coils, and vascular grafts—tools essential for intricate procedures like repairing damaged blood vessels or preventing life-threatening aneurysms. By aligning with cutting-edge technological advancements and rigorous clinical testing, MicroPort Endovascular has cemented its reputation as a trusted partner for medical professionals seeking reliable, effective, and technologically advanced instruments. MicroPort Endovascular’s revenue model is intrinsically linked to the global demand for cardiovascular solutions. With increasing incidences of cardiovascular diseases, partly due to lifestyle shifts and an aging population, the firm strategically positions itself in both domestic and international markets to capitalize on this demand. Their business operations span research and development, manufacturing, and distribution, allowing them to maintain control over quality and innovation while optimizing costs. Revenue flows from direct sales to hospitals and healthcare providers, as well as partnerships with distributors, ensuring widespread market penetration. Their continuous investment in R&D not only drives the introduction of new products but also enhances existing ones, thereby maintaining a competitive edge in a field where innovation is tantamount to success.

Intrinsic Value
176.77 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Net Income (Common)?
Net Income (Common)
492.4m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicroPort Endovascular MedTech Group Co Ltd's Net Income (Common) amounts to 492.4m CNY.

What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
40%

Over the last year, the Net Income (Common) growth was 38%. The average annual Net Income (Common) growth rates for Shanghai MicroPort Endovascular MedTech Group Co Ltd have been 32% over the past three years , 40% over the past five years .

Back to Top